Machine Learning

A pivotal trial success in lupus for BTK inhibitor orelabrutinib not only offers new hope for patients but also validates Zenas BioPharma's strategy.

The crypto giant reports massive growth, but a pivot to AI, operational fires, and rising debt reveal a risky strategy to reshape global computing power.

Palantir's DGSI contract renewal isn't just a deal; it's a story of strategic reliance, political tension, and the bedrock of its business model.

California's Movandi is moving to Riyadh. A look at how sovereign incentives are building a new semiconductor hub and the wireless backbone for an AI future.

Beyond the runway hype, AI is now a core driver of commerce. But does it level the playing field or just raise the stakes for everyone involved?

indie Semiconductor is aggressively using stock grants to lure top engineers for its ADAS future. But what is the cost of this talent war for investors?

United Imaging Intelligence's new AI agents can reason, act, and report. But are hospitals ready for the business and ethical hurdles of this new era?

A Chinese environmental giant and a Singaporean robotics upstart join forces. Can their automated solutions really clean up the world's dirtiest jobs?

With a $157M expansion, Hyosung aims to build the USA's largest transformer plant, tackling an energy crisis fueled by AI and an aging infrastructure.

A hybrid law firm just won a top ABA award by building a tech platform to help disabled Americans navigate bureaucracy. Is this the future of legal access?

Creekstone Energy plans to add 2 gigawatts of nuclear power to its Utah Gigasite, a bold move to satisfy AI's insatiable energy appetite.

Tech Mahindra's Global Chess League is partnering with AWS, using AI and smart broadcasting to transform the ancient game into a high-tech spectator sport.

A South Korean firm has solved a hidden flaw in industrial magnets, promising a leap in efficiency for battery, recycling, and mining industries.

Long Beach's new Black-Serving Institution status isn't just an equity win; it's a strategic investment in the diverse STEM talent America's defense sector needs.

The private capital market leader's latest user-voted award reveals a major trend: authentic customer feedback is the new currency in high-stakes investing.

Serina Therapeutics poaches a top chemist to expand its POZ platform, signaling a major push beyond Parkinson's into new, high-value drug markets.

As John Lindsay retires, H&P anoints tech-savvy insider Trey Adams. A look at how this smooth transition secures a legacy of innovation.

Tenaya Therapeutics unveils promising interim data for its ARVC gene therapy, TN-401, hinting at a potential cure and igniting investor interest.

Tenaya Therapeutics seeks fresh capital to advance its heart disease pipeline, but the offering's structure raises dilution questions for investors.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.